# Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT07096362** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** Gemcitabine
- **DRUG:** Nab Paclitaxel
- **DIAGNOSTIC_TEST:** Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay

## Key facts

- **NCT ID:** NCT07096362
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2030-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096362, "Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07096362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*